MyD88-mediated stabilization of interferon-γ-induced cytokine and chemokine mRNA

Nature Immunology

Volumn 7, Issue 4, 2006, Pages 375-381

  Sun, Dongxu ^a   Ding, Aihao ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 1 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MIXED LINEAGE KINASE 3; MYELOID DIFFERENTIATION FACTOR 88; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; URIDINE;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENETIC CODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CHEMOKINES, CXC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN D; INTERFERON-GAMMA, RECOMBINANT; MACROPHAGES, PERITONEAL; MAP KINASE KINASE 3; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYELOID DIFFERENTIATION FACTOR 88; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, INTERFERON; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645101274     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni1308     Document Type: Article

References (56)

1. Nathan, C.F. Secretory products of macrophages. J. Clin. Invest. 79, 319-326 (1987).
2. Han, J. & Ulevitch, R.J. Limiting inflammatory responses during activation of innate immunity. Nat. Immunol. 6, 1198-1205 (2005).
3. Wilusz, C.J., Wormington, M. & Peltz, S.W. The cap-to-tail guide to mRNA turnover. Nat. Rev. Mol. Cell Biol. 2, 237-246 (2001).
4. Lam, L.T. et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2, 1-11 (2001).
5. Grigull, J., Mnaimneh, S., Pootoolal, J., Robinson, M.D. & Hughes, T.R. Genome-wide analysis of mRNA stability using transcription inhibitors and microarrays reveals posttranscriptional control of ribosome biogenesis factors. Mol. Cell. Biol. 24, 5534-5547 (2004).
6. Shaw, G. & Kamen, R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46, 659-667 (1986).
7. Treisman, R. Transient accumulation of c-fos RNA following serum stimulation requires a conserved 5′ element and c-fos 3′ sequences. Cell 42, 889-902 (1985).
8. Gingerich, T.J., Feige, J.J. & LaMarre, J. AU-rich elements and the control of gene expression through regulated mRNA stability. Anim. Health Res. Rev. 5, 49-63 (2004).
9. Datta, S., Novotny, M., Li, X., Tebo, J. & Hamilton, T.A. Toll IL-1 receptors differ in their ability to promote the stabilization of adenosine and uridine-rich elements containing mRNA. J. Immunot. 173, 2755-2761 (2004).
10. Bakheet, T., Frevel, M., Williams, B.R., Greer, W. & Khabar, K.S. AIRED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res. 29, 246-254 (2001).
11. Brennan, C.M. & Steitz, J.A. HuR and mRNA stability. Cell. Mol. Life Sci. 58, 266-277 (2001).
12. Lai, W.S. et al. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor-α mRNA. Mol. Cell. Biol. 19, 4311-4323 (1999).
13. Jing, Q. et al. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120, 623-634 (2005).
14. Carballo, E., Lai, W.S. & Blackshear, P.J. Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science 281, 1001-1005 (1998).
15. Tchen, C.R., Brook, M., Saklatvala, J. & Clark, A.R. The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself. J. Biol. Chem. 279, 32393-32400 (2004).
16. Gouble, A. et al. A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumongenesis in transgenic mice. Cancer Res. 62, 1489-1495 (2002).
17. Taylor, G.A. et al. A pathogenetic role for TNF-α in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4, 445-454 (1996).
18. Kontoyiannis, D., Pasparalkis, M., Pizarro, T.T., Cominelli, F. & Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
19. Mahtani, K.R. et al. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor-α mRNA stability. Mol. Cell. Biol. 21, 6461-6469 (2001).
20. Frevel, M.A. et al. p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol. Cell. Biol. 23, 425-436 (2003).
21. Winzen, R. et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18, 4969-4980 (1999).
22. Neininger, A. et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem. 277, 3065-3068 (2002).
23. Stoecklin, G. et al. MK2-induced tristetraprolin;14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J. 23, 1313-1324 (2004).
24. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
25. Darnell, J.E., Jr., Kerr, I.M. & Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421 (1994).
26. Shi, S. et al. MyD88 primes macrophages for full-scale activation by interferon-γ yet mediates few responses to Mycobacterium tuberculosis. J. Exp. Med. 198, 987-997 (2003).
27. Meraz, M.A. et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442 (1996).
28. Shuai, K., Schindler, C., Prezioso, V.R. & Darnell, J.E., Jr. Activation of transcription by IFN-γ: Tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258, 1808-1812 (1992).
29. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424, 743-748 (2003).
30. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640-643 (2003).
31. Ichijo, H. et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90-94 (1997).
32. Teramoto, H. et al. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J. Biol. Chem. 271, 27225-27228 (1996).
33. Sato, S. et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171, 4304-4310 (2003).
34. Wesche, H., Henzel, W.J., Shillinglaw, W., Li, S. & Cao, Z. MyD88: An adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7, 837-407 (1997).
35. Medzhitov, R. et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2, 253-258 (1998).
36. Morrison, D.K. & Davis, R.J. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 19, 91-118 (2003).
37. Whitmarsh, A.J., Cavanagh, J., Tournier, C., Yasuda, J. & Davis, R.J. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281, 1671-1674 (1998).
38. Goh, K.C., Haque, S.J. & Williams, B.R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18, 5601-5608 (1999).
39. Janssens, S. & Beyaert, R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell 11, 293-302 (2003).
40. Gallo, K.A. & Johnson, G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3, 663-672 (2002).
41. Roy, S.K. et al. A role for mixed lineage kinases in regulating transcription factor CCAAT/enhancer-binding protein-β-dependent gene expression in response to interferon-γ. J. Biol. Chem. 280, 24462-24471 (2005).
42. Jefferies, C.A. et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by Toll-like receptor 4. J. Biol. Chem. 278, 26258-26264 (2003).
43. Ojaniemi, M. et al. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 33, 597-605 (2003).
44. Honda, K. et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. USA 101, 15416-15421 (2004).
45. Wang T.Y., Gu, S., Ronni, T., Du, Y. & Chen, X. In vivo dual-tagging proteome approach in studying signaling pathways in immune response. J. Proteome Res. 4, 941-949 (2005).
46. Kawai, T. et al. Lipopolysaccharide stimulates the MyD88-independent pathway and resufts in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167, 5887-5894 (2001).
47. Yamamoto, M. et al. Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169, 6668-6672 (2002).
48. Hoshino, K., Kaisho, T, Iwabe, T., Takeuchi, O. & Akira, S. Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation. Int. Immunol. 14, 1225-1231 (2002).
49. Verma, A. et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growh factor-β on normal hematopoiesis. J. Biol. Chem. 277, 7726-7735 (2002).
50. Scanga, C.A. et al. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect. Immun. 72, 2400-2404 (2004).
51. Fremond, C.M. et al. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J. Clin. Invest. 114, 1790-1799 (2004).
52. Shi, S. et al. Expression of many immunologically important genes in Mycobacterium tuberculosis-infected macrophages is independent of both TLR2 and TLR4 but dependent on IFN-αβ receptor and STAT1. J. Immunol. 175, 3318-3328 (2005).
53. Mogues, T., Goodrich, M.E., Ryan, L., LaCourse, R. & North, R.J. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193, 271-280 (2001).
54. Williams, B.R. Signal integration via PKR. Sci. STKE 3 July 2001 (doi:10.1126/stke.2001.89.re2).
55. Jin, F.Y., Nathan, C., Radzioch, D. & Ding, A. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88, 417-426 (1997).
56. Ehrt, S. et al. Reprogramming of the macrophage transcriptome in response to interferon-γ and Mycobacterium tuberculosis: Signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med. 194, 1123-1140 (2001).